Evogene Ltd.
EVGN Nasdaq· Agricultural Chemicals
Last close · Oct 30, 2026
$0.37
KIRA · Stoqly’s AI analyst, in plain words
- Evogene Ltd. had only $3.9M of revenue in fiscal 2025: it is still developing what it sells. It spent $8.0M on research and development, 45% of its operating costs.
- Its operating margin was −364.2%, down 27.1 pts: of every 100 in sales, about −364 is left after running the business.
- Evogene Ltd. lost $8.5M in fiscal 2025. With no meaningful sales yet, it pays for its work from the cash it holds.
- Free cash flow was −$13.6M in fiscal 2025, −353.9% of revenue. At that burn of $13.6M a year, its $13.0M of cash and short-term investments would last about 1.0 years.
Market cap
$2.9M
P/E
0.3x
Revenue
$3.9M
Net income
−$8.5M
Free cash flow
−$13.6M
Operating margin
−364.2%
Evogene Ltd. in 30 seconds · fiscal 2025
Are shareholders being diluted?
+38.2%
A lot. The share count rose 38.2% last year, so each share owns noticeably less.
Does it make a profit?
$8.0M R&D
Not yet: it has no meaningful sales. It spent $8.0M on research and development, 45% of its operating costs.
How long would its cash last?
1.0 yrs
Not long. It burns $13.6M a year and holds $13.0M, under a year at that pace, so it may need new money soon.
How healthy are the accounts?
2 / 8
It passes 2 of 8 health tests, but most of them need sales, so the score says little before revenue starts.
How is the share priced?
0.3x
One share costs 0.3 times its yearly profit per share.
What Evogene Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 26, 2026
- Legal name
- Evogene Ltd.
- CIK
- 0001574565
Evogene Ltd. · EVGN · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.9M | $1.7M | $3.0M | $5.6M | $3.9M |
| Revenue growth | −10.6% | 80.1% | 78.0% | 87.0% | −30.9% |
| Gross margin | 17.5% | 45.7% | 50.0% | 57.3% | −6.3% |
| Operating margin | −3,328.3% | −1,608.4% | −745.5% | −337.2% | −364.2% |
| Net income | −$27.8M | −$26.6M | −$23.9M | −$16.5M | −$8.5M |
| Net margin | −2,988.5% | −1,590.3% | −800.8% | −295.6% | −220.2% |
| Diluted EPS | −$0.69 | −$6.44 | −$5.20 | −$2.90 | $1.08 |
| Cash | |||||
| Cash from operations | −$24.7M | −$23.7M | −$21.6M | −$19.7M | −$13.5M |
| Capital expenditure | $0.8M | $1.2M | $0.6M | $0.6M | $0.1M |
| Free cash flow | −$25.6M | −$24.8M | −$22.2M | −$20.3M | −$13.6M |
| FCF margin | −2,748.7% | −1,483.5% | −742.9% | −364.5% | −353.9% |
| Share count change | 43.6% | −89.8% | 10.8% | 24.1% | 38.2% |
| Debt and strength | |||||
| Cash and short-term investments | $32.3M | $29.0M | $20.8M | $15.3M | $13.0M |
| Shareholders' equity | $53.7M | $27.9M | $12.1M | −$1.5M | −$0.1M |
| Current ratio | 8.3x | 6.7x | 5.0x | 1.2x | 4.5x |
| Interest coverage | −21.9x | −8.1x | −24.0x | −5.6x | −7.3x |
| Returns and quality | |||||
| Return on equity | −55.8% | −65.3% | −119.4% | −311.0% | — |
| Return on tangible equity | −72.3% | −193.2% | — | — | — |
| Piotroski F-score | 2 | 4 | 4 | 3 | 2 |
| Altman Z'' | −4.8 | −12.0 | −15.3 | −25.2 | −46.7 |
Insiders bought, 12 months
$0.7M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Evogene Ltd. · EVGN · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.37 a share, the company is worth $2.9M: 0.3 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001574565). Latest version: stoqly.net/companies/evgn. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.